Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - chloride, quantity: 102.5 mmol/l; lactate, quantity: 35 mmol/l; sodium chloride, quantity: 5.786 g/l; calcium, quantity: 1.25 mmol/l; sodium, quantity: 134 mmol/l; sodium lactate, quantity: 3.925 g/l; calcium chloride dihydrate, quantity: 0.1838 g/l; magnesium, quantity: 0.5 mmol/l; magnesium chloride hexahydrate, quantity: 0.1017 g/l; glucose monohydrate, quantity: 46.75 g/l - solution, irrigation - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - for use as a peritoneal dialysis solution in the management of end stage renal disease and acute renal failure.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - glucose monohydrate, quantity: 16.5 g/l; magnesium chloride hexahydrate, quantity: 0.1017 g/l; calcium chloride dihydrate, quantity: 0.1838 g/l; lactate, quantity: 35 mmol/l; calcium, quantity: 1.25 mmol/l; chloride, quantity: 102.5 mmol/l; magnesium, quantity: 0.5 mmol/l; sodium lactate, quantity: 3.925 g/l; sodium, quantity: 134 mmol/l; sodium chloride, quantity: 5.786 g/l - solution, irrigation - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections - for use as a peritoneal dialysis solution in the management of end stage renal disease and acute renal failure.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tofacitinib citrate, quantity: 1.62 mg/ml (equivalent: tofacitinib, qty 1 mg/ml) - solution - excipient ingredients: xylitol; lactic acid; sucralose; sodium benzoate; hydrochloric acid; purified water; flavour - rheumatoid arthritis (ra),xeljanz is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. xeljanz can be used alone or in combination with conventional synthetic disease-modifying antirheumatic drugs (dmards), including methotrexate.,psoriatic arthritis (psa),xeljanz in combination with conventional synthetic dmards is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response to a prior dmard therapy.,ulcerative colitis (uc),xeljanz is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.,ankylosing spondylitis (as),xeljanz is indicated for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.,juvenile idiopathic arthritis (jia),xeljanz is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis, extended oligoarthritis and systemic juvenile arthritis without systemic features for six months) and juvenile psoriatic arthritis in patients 2 years of age and older, who have responded inadequately to previous therapy with dmards.

Filippseyjar - enska - FDA (Food And Drug Administration)

n/a; importer: one dexcel pharma inc.; distributor: one dexcel pharma inc. - lactated ringer's solution - solution for i.v. infusion - formulation: each 100 ml solution contains: sodium lactate (60%) solution 533 g equivalent to 320 g sodium lactate sodium chloride 600 g potassium chloride 40 g calcium chloride 27 g

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methylprednisolone hydrogen succinate ph. eur. - powder and solvent for solution for injection/infusion - 40 milligram/vial - glucocorticoids; methylprednisolone

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methylprednisolone hydrogen succinate ph. eur. - powder and solvent for solution for injection/infusion - 500 milligram/vial - glucocorticoids; methylprednisolone

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methylprednisolone - powder and solvent for solution for injection/infusion - 125 milligram/vial - glucocorticoids; methylprednisolone

Írland - enska - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methylprednisolone hydrogen succinate ph. eur. - powder and solvent for solution for injection/infusion - 1000 milligram/vial - glucocorticoids; methylprednisolone

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - methylprednisolone sodium succinate - powder and solvent for solution for injection - 500mg